Product Name |
5-HT7 Receptor |
5-HT1 Receptor |
5-HT2 Receptor |
5-HT3 Receptor |
5-HT5 Receptor |
5-HT6 Receptor |
5-HT4 Receptor |
5-HT7 Receptor Selectivity |
Purity |
SB-269970 hydrochloride |
|
|
|
|
|
|
|
Selective Antagonist
|
98.77% |
Lurasidone |
5-HT7 Receptor, IC50: 0.495 nM
|
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
|
Selective Modulator
|
99.49% |
Asenapine maleate |
5-HT7 Receptor, Ki: 0.13 nM
|
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
Selective Antagonist
|
99.95% |
Lurasidone Hydrochloride |
5-HT7 Receptor, IC50: 0.495 nM
|
5-HT1A Receptor, IC50: 6.75 nM
|
|
|
|
|
|
Selective Modulator
|
99.87% |
SB 258719 |
|
|
|
|
|
|
|
Selective Antagonist
|
≥99.0% |
Asenapine hydrochloride |
5-HT7 Receptor, Ki: 0.13 nM
|
|
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
Selective Antagonist
|
98.76% |
JNJ-18038683 |
Rat 5-HT7 Receptor, pKi: 8.19 (in HEK293 cells )
Human 5-HT7 Receptor , pKi: 8.20 (in HEK293 cells )
|
|
|
|
|
|
|
Selective Antagonist
|
99.21% |
SB-269970 |
Human 5-HT7 Receptor , pKi: 8.3
|
|
|
|
|
|
|
Selective Antagonist
|
|
AS19 |
Human 5-HT7 Receptor , IC50: 0.83 nM
Human 5-HT7 Receptor , Ki: 0.6 nM
|
5-HT1A Receptor, Ki: 89.7 nM
5-HT1B Receptor, Ki: 490 nM
5-HT1D Receptor, Ki: 6.6 nM
|
|
|
5-HT5 Receptor, Ki: 98.5 nM
|
|
|
Selective Agonist
|
≥99.0% |
8-OH-DPAT |
5-HT7 Receptor, Ki: 466 nM
|
5-HT1A Receptor, pIC50: 8.19
|
|
|
|
|
|
Pan Agonist
|
≥98.0% |
Methiothepin mesylate |
5-HT7 Receptor, pKd: 8.99
|
5-HT1A Receptor, pKd: 7.10
5-HT1B Receptor, pKd: 7.28
5-HT1C Receptor, pKd: 7.56
5-HT1D Receptor, pKd: 6.99
|
5-HT2A Receptor, pKi: 8.50
5-HT2B Receptor, pKi: 8.68
5-HT2C Receptor, pKi: 8.35
|
|
5-HT5A Receptor, pKd: 7.0
5-HT5B Receptor, pKd: 7.8
|
5-HT6 Receptor, pKd: 8.74
|
|
Pan Antagonist
|
≥98.0% |
Vortioxetine hydrobromide |
5-HT7 Receptor, Ki: 19 nM
|
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
|
Pan Inhibitor
|
99.94% |
LP-211 |
5-HT7 Receptor, Ki: 0.58 nM
|
5-HT1A Receptor, Ki: 188 nM
|
|
|
|
|
|
Pan Agonist
|
99.61% |
Vortioxetine |
Human 5-HT7 Receptor , Ki: 19 nM
|
|
|
5-HT3A Receptor, Ki: 3.7 nM
|
|
|
|
Pan Inhibitor
|
99.52% |
Iloperidone |
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 μM
|
|
Pan Antagonist
|
99.64% |
Rotigotine |
5-HT7 Receptor, Ki: 86 nM
|
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
|
Pan Agonist
|
99.98% |
Asenapine |
|
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
5-HT2A Receptor, pKi: 10.2
5-HT2C Receptor, pKi: 10.5
5-HT2B Receptor, pKi: 9.8
|
|
|
|
|
Pan Antagonist
|
98.81% |
BRL 54443 |
5-HT7 Receptor, Ki: >10,000 nM
|
5-HT1E Receptor, Ki: 1.1 nM
5-HT1F Receptor, Ki: 0.7 nM
5-HT1A Receptor, Ki: 63 nM
5-HT1B Receptor, Ki: 126 nM
5-HT1D Receptor, Ki: 63 nM
|
5-HT2A Receptor, Ki: 1259 nM
5-HT2B Receptor, Ki: 100 nM
5-HT2C Receptor, Ki: 316 nM
|
|
|
5-HT6 Receptor, Ki: >10,000 nM
|
|
Pan Agonist
|
99.39% |
Nuciferine |
5-HT7 Receptor, IC50: 150 nM
|
5-HT1A Receptor, EC50: 3.2 μM
|
5-HT2C Receptor, IC50: 131 nM
5-HT2A Receptor, IC50: 478 nM
5-HT2B Receptor, IC50: 1 μM
|
|
|
5-HT6 Receptor, EC50: 700 nM
|
|
Pan Modulator
|
99.66% |
Rotigotine Hydrochloride |
5-HT7 Receptor, Ki: 86 nM
|
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
|
Pan Agonist
|
≥95.0% |
SEP-363856 hydrochloride |
5-HT7 Receptor, EC50: 6.7 μM
|
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
|
Pan Agonist
|
99.78% |
GSK163090 |
Human 5-HT7 Receptor , pKi: 6.8
|
5-HT1A Receptor, pKi: 9.4
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pKi: 9.7
|
5-HT2A Receptor, pKi: 6
5-HT2B Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 5.8
|
|
|
Human 5-HT6 Receptor, pKi: <5.3
|
|
Pan Antagonist
|
99.95% |
Adoprazine |
|
5-HT1A Receptor, pEC50: 9
5-HT1A Receptor, pKi: 9.1
|
|
|
|
|
|
Pan Agonist
|
98.10% |
SB 271046 Hydrochloride |
5-HT7 Receptor, pKi: 5.39
|
5-HT1D Receptor, pKi: 6.55
5-HT1A Receptor, pKi: 6.35
5-HT1B Receptor, pKi: 6.05
5-HT1F Receptor, pKi: 5.95
5-HT1E Receptor, pKi: <4.99
|
5-HT2A Receptor, pKi: 5.62
5-HT2B Receptor, pKi: 5.41
Human 5-HT2C Receptor, pKi: 5.73
|
|
|
5-HT6 Receptor, pKi: 8.92-9.02
|
5-HT4 Receptor, pKi: 5.27
|
Pan Antagonist
|
98.64% |
SB 243213 dihydrochloride |
Human 5-HT7 Receptor , pKi: 5.64
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
|
Pan Antagonist
|
≥99.0% |
SB 243213 hydrochloride |
Human 5-HT7 Receptor , pKi: 5.64
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
|
Pan Antagonist
|
|
5-HT6/7 antagonist 1 |
|
|
|
|
|
|
|
Pan Antagonist
|
|
SEP-363856 |
5-HT7 Receptor, EC50: 6.7 μM
|
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
|
|
|
|
Pan Agonist
|
|
SB 243213 |
Human 5-HT7 Receptor , pKi: 5.64
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
|
Pan Antagonist
|
98.62% |
ST1936 oxalate |
Human 5-HT7 Receptor , Ki: 168 nM
|
|
5-HT2B Receptor, Ki: 245 nM
|
|
|
5-HT6 Receptor, Ki: 13 nM
|
|
Pan Agonist
|
|
5-Carboxamidotryptamine maleate |
|
5-HT1A Receptor
5-HT1B Receptor
5-HT1D Receptor
|
|
|
|
|
|
Pan Agonist
|
|
AP521 |
5-HT7 Receptor, IC50: 198 nM (in rat)
|
5-HT1A Receptor, IC50: 94 nM (in human)
5-HT1A Receptor, IC50: 135 nM (in rat)
5-HT1B Receptor, IC50: 254 nM (in rat)
5-HT1B Receptor, IC50: 5530 nM (in human)
5-HT1D Receptor, IC50: 418 nM (in human)
|
|
|
5-HT5A Receptor, IC50: 422 nM (in human)
|
|
|
Pan Agonist
|
|
5-HT7 agonist 1 |
|
|
|
|
|
|
|
Pan Agonist
|
|
Brilaroxazine |
5-HT7 Receptor, Ki: 2.7 nM
|
5-HT1A Receptor, Ki: 1.5 nM
|
5-HT2A Receptor, Ki: 2.5 nM
5-HT2B Receptor, Ki: 0.19 nM
|
|
|
|
|
Pan Modulator
|
|
Sarizotan |
5-HT7 Receptor, IC50: 10 nM (human)
|
5-HT1D Receptor, IC50: 500 nM (calf)
5-HT1A Receptor, IC50: 6.5 nM (rat)
5-HT1A Receptor, IC50: 0.1 nM (human)
5-HT1B Receptor, IC50: 600 nM (rat)
|
5-HT2A Receptor, IC50: 960 nM (rat, agonist site)
5-HT2A Receptor, IC50: 587 nM (human, antagonist site)
5-HT2C Receptor, IC50: 800 nM (pig)
5-HT2B Receptor, IC50: 108 nM (human)
|
5-HT3 Receptor, IC50: 3500 nM (NG 108 cells)
|
5-HT5A Receptor, IC50: 313 nM (human)
|
5-HT6 Receptor, IC50: 3300 nM (human)
|
|
Pan Agonist
|
|
Iloperidone hydrochloride |
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 nM
|
|
Pan Antagonist
|
|